<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04533997</url>
  </required_header>
  <id_info>
    <org_study_id>SSH-IC</org_study_id>
    <nct_id>NCT04533997</nct_id>
  </id_info>
  <brief_title>Hypertonic Saline Therapy in Ambulatory Heart Failure Unit.</brief_title>
  <official_title>Efficacy and Safety of Ambulatory Hypertonic Saline Therapy in Outpatient Heart Failure Units.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Puerta de Hierro University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spanish Society of Cardiology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Puerta de Hierro University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare intravenous furosemide (125 to 250 mg), isolated or&#xD;
      in combination with hypertonic saline solution (2.4% to 3.6%) in the outpatient heart failure&#xD;
      patient. The hypothesis is that the combination therapy will increase the diuresis volume at&#xD;
      3 hours and improve congestion parameters at 7 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, multicenter study of all consecutive patients with&#xD;
      decompensated heart failure and signs of volume overload who do not require hospital&#xD;
      admission but require intravenous diuretic for relief of congestion.&#xD;
&#xD;
      Patients meeting the inclusion criteria, with prior informed consent, will be randomized to&#xD;
      treatment with furosemide with hypertonic saline versus isolated furosemide (control group).&#xD;
&#xD;
      Complete clinical evaluation, echocardiography, and blood and urinary tests will be performed&#xD;
      before the treatment. After 3 hours, diuresis volume, weight and urinary parameters will be&#xD;
      evaluated. Efficacy and safety visits will be performed at 7 and 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diuresis volume (ml)</measure>
    <time_frame>3 hours after treatment</time_frame>
    <description>Total diuresis volume after 3 hours of therapy administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight difference (kg)</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight difference (kg)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EVEREST congestion score</measure>
    <time_frame>7 days</time_frame>
    <description>Composite of dyspnoea (0-3), orthopnoea (0-3), fatigue (0-3), jugular venous distension (0-3), fatigue (0-3), rales (0-3), oedema (0-3). Higher score: worse congestion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inferior cava vein diameter (mm)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of B-lines in lung ultrasound</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in New York Heart Association</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NTproBNP and Cancer Antigen 125 levels</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoconcentration Parameters</measure>
    <time_frame>7 days</time_frame>
    <description>Hematocrit, Albumin and total Proteins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urinary Sodium</measure>
    <time_frame>7 days</time_frame>
    <description>Change in Urinary Sodium measured in a spot urinary sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>7 days</time_frame>
    <description>Need of new intravenous diuretic (outpatient clinic or emergency department). Heart Failure hospitalization. Cardiovascular mortality. All-Cause mortality or hospitalization. Worsening of kidney function: defined as an increase in creatinine ≥ 0.3 mg / dl.&#xD;
Electrolyte abnormalities defined as hypokalemia (K+ less than 3.5 milliequivalent / L) or hyperkalemia (K+ greater than 5.5 milliequivalent /L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>Need of new intravenous diuretic (outpatient clinic or emergency department). Heart Failure hospitalization. Cardiovascular mortality. All-Cause mortality or hospitalization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Intravenous furosemide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertonic saline solution plus intravenous furosemide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertonic saline solution plus intravenous furosemide</intervention_name>
    <description>Intravenous 60-minutes of hypertonic saline therapy plus furosemide:&#xD;
Furosemide:&#xD;
125 mg if home oral furosemide &lt; 160 mg, 250 mg if home oral furosemide ≥ 160 mg&#xD;
Hypertonic saline solution:&#xD;
Na+ 125-134: 3.6%, Na+ 135-145: 2.4%</description>
    <arm_group_label>Hypertonic saline solution plus intravenous furosemide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous furosemide</intervention_name>
    <description>Intravenous 60-minutes infusion of furosemide:&#xD;
125 mg if home oral furosemide &lt; 160 mg, 250 mg if home oral furosemide ≥ 160 mg</description>
    <arm_group_label>Intravenous furosemide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previous heart failure diagnosis (according to current European Guidelines)&#xD;
&#xD;
          -  Stable treatment in the previous 4 weeks (except diuretic).&#xD;
&#xD;
          -  Home oral treatment of ≥80 mg of furosemide/day or equivalent (40 mg furosemide = 20&#xD;
             mg of torasemide).&#xD;
&#xD;
          -  Transthoracic echocardiogram performed in the last year.&#xD;
&#xD;
          -  Congestive signs.The presence of two of the following congestion criteria will be&#xD;
             required: jugular pressure&gt; 10 cm, lower limb edema, ascites, or pleural effusion&#xD;
&#xD;
          -  Elevation of natriuretic peptides (NTproBNP&gt; 1000 pg / mL or B-type natriuretic&#xD;
             peptide&gt; 250 pg / ml) performed in a previous period of no more than 24 hours.&#xD;
&#xD;
          -  Need for intravenous diuretic therapy to relieve congestion according to the&#xD;
             responsible physician.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hospital admission criteria in the opinion of the responsible physician.&#xD;
&#xD;
          -  Systolic blood pressure &lt;90 mmHg or&gt; 180 mmHg.&#xD;
&#xD;
          -  Heart rate&gt; 150 bpm.&#xD;
&#xD;
          -  Basal oxygen saturation less than 90%.&#xD;
&#xD;
          -  Cardiogenic shock.&#xD;
&#xD;
          -  Acute Pulmonary Edema.&#xD;
&#xD;
          -  Clinically significant arrhythmia.&#xD;
&#xD;
          -  Acute myocardial ischemia.&#xD;
&#xD;
          -  Patients in hemodialysis or peritoneal dialysis program.&#xD;
&#xD;
          -  Serum sodium &lt;125 milliequivalent / L or&gt; 145 milliequivalent / L.&#xD;
&#xD;
          -  Serum potassium &lt; 3.5 milliequivalent/ L.&#xD;
&#xD;
          -  Hemoglobin &lt; 9 g / dL&#xD;
&#xD;
          -  Acute coronary syndrome or cardiological procedure in the previous 4 weeks.&#xD;
&#xD;
          -  Severe uncorrected valve disease except tricuspid regurgitation.&#xD;
&#xD;
          -  Moderate or severe dementia, active delirium or psychiatric problems.&#xD;
&#xD;
          -  Patients in whom cardiac surgery or device implantation is planned in the following 30&#xD;
             days.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Inability to give informed consent in the absence of a legal officer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Cobo Marcos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Puerta de Hierro. Madrid. Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marta Cobo Marcos, MD</last_name>
    <phone>0034911917747</phone>
    <email>martacobomarcos@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Cobo Marcos, MD</last_name>
      <phone>0034676743454</phone>
      <email>martacobomarcos@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Rey Juan Carlos</name>
      <address>
        <city>Móstoles</city>
        <state>Madrid</state>
        <zip>28933</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elvira Barrios Garrido-Lestache</last_name>
    </contact>
    <investigator>
      <last_name>Elvira Barrios Garrido-Lestache</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Santa Pau (Fundación Privada Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Zegri-Reiriz, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Isabel Zegri-Reiriz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santiago Jiménez Marrero</last_name>
    </contact>
    <investigator>
      <last_name>Santiago Jiménez Marrero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Ortiz Cortés</last_name>
    </contact>
    <investigator>
      <last_name>Carolina Ortiz Cortés</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Arnau de Vilanova</name>
      <address>
        <city>Lérida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Luis Morales-Rull</last_name>
    </contact>
    <investigator>
      <last_name>Jose Luis Morales-Rull</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pablo Díez Villanueva</last_name>
    </contact>
    <investigator>
      <last_name>Pablo Díez Villanueva</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernando Alfonso Manterola</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susana del Prado Díaz</last_name>
    </contact>
    <investigator>
      <last_name>Susana del Prado Díaz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandra Restrepo Córdoba</last_name>
    </contact>
    <investigator>
      <last_name>Alejandra Restrepo Córdoba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Doce de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier De Juan Bagudá</last_name>
    </contact>
    <investigator>
      <last_name>Javier De Juan Bagudá</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Manuel García Pinilla</last_name>
    </contact>
    <investigator>
      <last_name>Jose Manuel García Pinilla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio Núñez Villota</last_name>
    </contact>
    <investigator>
      <last_name>Julio Núñez Villota</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Pérez Silvestre</last_name>
    </contact>
    <investigator>
      <last_name>José Pérez Silvestre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Lozano de Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Rubio Gracia</last_name>
    </contact>
    <investigator>
      <last_name>Jorge Rubio Gracia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 23, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Puerta de Hierro University Hospital</investigator_affiliation>
    <investigator_full_name>Marta Cobo Marcos</investigator_full_name>
    <investigator_title>Cardiologist</investigator_title>
  </responsible_party>
  <keyword>Hypertonic Saline Solution</keyword>
  <keyword>Outpatient Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

